ATOS

ATOSSA THERAPEUTICS, INC. - 10-Q Summary (Q1 2026)

Business Context and Reporting Period

This report covers the quarterly period ended March 31, 2026. Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing proprietary medicines for breast cancer and rare diseases. The company's lead candidate is oral (Z)-endoxifen, currently in Phase 2 clinical development for breast cancer, Duchenne muscular dystrophy (DMD), and McCune-Albright Syndrome (MAS). The company is a non-accelerated filer and a smaller reporting company.

Key Financial Metrics

Material Changes vs. Prior Period

• Increased Operating Loss: Net loss increased by approximately $2.9 million (43%) compared to Q1 2025, driven by higher operating expenses.
• Expense Breakdown:
  • R&D Expenses: Increased $0.6 million (15%) to $4.8 million, primarily due to higher clinical trial and drug development costs.
  • G&A Expenses: Increased $1.8 million (56%) to $5.1 million. This was largely driven by a $1.8 million increase in legal fees related to patent litigation (subsequently settled) and IP management.
• Cash Burn: Cash used in operating activities increased by $3.6 million year-over-year due to increased clinical spend and professional fees.
• Reverse Stock Split: On February 2, 2026, the company effected a 1-for-15 reverse stock split to regain compliance with Nasdaq listing standards. All share and per-share data have been retroactively restated.

Guidance, Outlook, and Risks

• Going Concern: The company has incurred net losses since inception and has not established an ongoing source of revenue. Management states that existing resources are likely insufficient to fund planned operations for the next 12 months. Substantial doubt exists regarding the company's ability to continue as a going concern without additional capital.
• Funding Strategy: The company plans to raise capital through equity sales (including a new $50 million "at-the-market" facility with Rodman & Renshaw effective March 31, 2026) or short-term borrowings. No sales were made under the new facility during Q1 2026.
• Legal Settlement: On April 13, 2026 (subsequent event), the company entered a Settlement Agreement with Intas Pharmaceuticals to resolve Post Grant Review (PGR) and Inter Partes Review (IPR) petitions regarding its Endoxifen patents. The settlement preserves the company's ability to develop (Z)-endoxifen in its principal focus areas.
• Clinical Outlook:
  • Karisma Study: Top-line durability data expected in Q2 2026.
  • I-SPY 2: Data from expanded arms expected in H2 2026.
  • Rare Diseases: Received FDA Rare Pediatric Disease and Orphan Drug designations for DMD and MAS, potentially qualifying for Priority Review Vouchers (PRV).
• Risks: Key risks include the inability to raise capital, failure of clinical trials, regulatory delays, and potential loss of Australian R&D tax rebates (a $1.1 million liability is recorded due to audit uncertainty).

Investor Verification Checklist

• Liquidity Runway: Verify the timeline for the next capital raise given the explicit statement that current cash ($31.7M) is insufficient for 12 months of operations.
• Legal Resolution: Confirm the final terms of the Intas settlement and ensure no further patent challenges remain pending that could block commercialization.
• Clinical Milestones: Monitor the release of Karisma durability data (expected Q2 2026) and I-SPY 2 data (expected H2 2026) for efficacy signals.
• Regulatory Designations: Track the status of Orphan Drug designations for DMD and MAS and the potential monetization of Priority Review Vouchers.
• Australian Tax Liability: Review the status of the $1.1 million liability related to Australian R&D tax rebates and any potential for additional accruals.